Key Highlights:
- Zydus Lifesciences has launched the world’s first biosimilar of Nivolumab in India under the brand name Tishtha, expanding access to immuno-oncology treatments.
- Tishtha will be available in 100 mg and 40 mg strengths priced at INR 28,950 and INR 13,950 respectively, around one-fourth the cost of the reference drug. The two-dose format allows oncologists to optimise dosing and reduce wastage during treatment.
- Developed and manufactured in India, the biosimilar is aimed at improving affordability, accessibility and continuity of care for patients undergoing immunotherapy, supporting broader access to advanced cancer treatment across the country.
Implications:
Tishtha detonates pricing bombs on Roche’s Tecentriq and MSD’s Opdivo, handing cash-strapped hospitals a lifeline while exploding patient volumes across Tier-2/3 oncology hubs.
Zydus seizes immuno-onco dominance from multinationals, forcing premium brands into defensive niche positioning as biosimilars capture mainstream solid tumor protocols.
Source: Expresspharma | Image: Zydus
Other Articles
Next
Previous
No Comment! Be the first one.